NCT03984097 2026-03-10A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)TakedaPhase 1 Active not recruiting50 enrolled